Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology

Thorsten H Ecke; Christina J Meisl; Thorsten Schlomm; Anja Rabien; Flora Labonté; Dezhi Rong; Sebastian Hofbauer; Frank Friedersdorff; Lilli Sommerfeldt; Nella Gagel; Andreas Gössl; Dimitri Barski; Thomas Otto; Camilla M Grunewald; Günter Niegisch; Martin J P Hennig; Mario W Kramer; Stefan Koch; Jenny Roggisch; Sarah Weiß; Michael Waldner; Johannes Graff; Elke Veltrup; Friederike Linden; Roland Hake; Sebastian Eidt; Ralph M Wirtz; Tobias Klatte

doi:10.1016/j.urology.2024.11.056

Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology

Urology. 2024 Dec 1:S0090-4295(24)01113-0. doi: 10.1016/j.urology.2024.11.056. Online ahead of print.

Authors

Thorsten H Ecke¹, Christina J Meisl², Thorsten Schlomm², Anja Rabien², Flora Labonté², Dezhi Rong³, Sebastian Hofbauer², Frank Friedersdorff⁴, Lilli Sommerfeldt⁵, Nella Gagel⁵, Andreas Gössl⁶, Dimitri Barski⁶, Thomas Otto⁷, Camilla M Grunewald⁸, Günter Niegisch⁸, Martin J P Hennig⁹, Mario W Kramer¹⁰, Stefan Koch¹¹, Jenny Roggisch¹², Sarah Weiß³, Michael Waldner¹³, Johannes Graff¹³, Elke Veltrup¹⁴, Friederike Linden¹⁴, Roland Hake¹⁵, Sebastian Eidt¹⁵, Ralph M Wirtz¹⁴, Tobias Klatte¹⁶

Affiliations

¹ Department of Urology, Helios Hospital, Bad Saarow, Germany; Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: thorsten.ecke@helios-gesundheit.de.
² Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
³ Department of Urology, Helios Hospital, Bad Saarow, Germany.
⁴ Department of Urology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany.
⁵ Department of Urology, Evangelisches Krankenhaus Königin Elisabeth Herzberge, Berlin, Germany.
⁶ Rheinland Klinikum Neuss, Department of Urology, Neuss, Germany.
⁷ Rheinland Klinikum Neuss, Department of Urology, Neuss, Germany; University Hospital Essen, Essen, Germany.
⁸ Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
⁹ Department of Urology, University Hospital Lübeck, Lübeck, Germany.
¹⁰ Department of Urology, Städtisches Klinikum Lüneburg, Lüneburg, Germany.
¹¹ Institute of Pathology, Helios Hospital, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany.
¹² Institute of Pathology, Helios Hospital, Bad Saarow, Germany.
¹³ Department of Urology, St. Elisabeth Hospital, Cologne, Germany.
¹⁴ STRATIFYER Molecular Pathology GmbH, Cologne, Germany.
¹⁵ Institute of Pathology, St. Elisabeth Hospital, Cologne, Germany.
¹⁶ Department of Urology, Helios Hospital, Bad Saarow, Germany; Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Brandenburg, Germany.

PMID: 39626834
DOI: 10.1016/j.urology.2024.11.056

Abstract

Objective: To compare all available rapid tests on a large cohort of recurrent bladder cancer during follow-up in this multicentre-study is the first study. BTA stat, NMP22 BladderChek, UBC Rapid Test CancerCheck UBC rapid VISUAL, and uromonitor are urinary-based rapid tests for bladder cancer detection.

Methods: In total, 187 urine samples were analyzed from patients with suspected recurrent non-muscle invasive urothelial bladder cancer on cystoscopy during follow-up in a real-world assessment. All suspicious lesions were resected with 110 samples showing recurrent urothelial cancer. Urine samples were analyzed by the BTA stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC rapid VISUAL, uromonitor, and cytology. Sensitivities and specificities were calculated by contingency analyses.

Results: All investigated urinary markers could detect a higher percentage of pathological results in urine of bladder cancer patients compared to urine of tumor free patients. The calculated diagnostic sensitivities for BTA stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC rapid VISUAL, uromonitor, and cytology were 60.0%, 10.0%, 58.0%, 32.0%, 54.5%, and 41.5% for non-muscle invasive low-grade, and 64.0%, 40.0%, 77.8%, 50.0%, 56.0%, and 65.5% for non-muscle invasive high-grade bladder cancer. The specificity was 51.3%, 94.8%, 66.2%, 89.5%, 94.9%, and 66.2%, respectively.

Conclusion: During follow-up sensitivities and specificities of most urinary markers are higher compared to cytology for the detection of recurrent bladder cancer. BTA stat, UBC Rapid Test, and uromonitor appear useful in this setting.